{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.85","upperLimit":"7.82","value":"6.6"},{"groupId":"OG001","lowerLimit":"7.16","upperLimit":"8.74","value":"8.3"}]}],"title":"Physical well-being"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.26","upperLimit":"13.37","value":"10.8"},{"groupId":"OG001","lowerLimit":"8.97","upperLimit":"13.83","value":"12.4"}]}],"title":"Social/family well-being"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.36","upperLimit":"11.30","value":"9.7"},{"groupId":"OG001","lowerLimit":"8.54","upperLimit":"12.52","value":"9.9"}]}],"title":"Emotional well-being"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.55","upperLimit":"7.43","value":"6.6"},{"groupId":"OG001","lowerLimit":"6.01","upperLimit":"8.34","value":"6.7"}]}],"title":"Functional well-being"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.62","upperLimit":"9.66","value":"8.7"},{"groupId":"OG001","lowerLimit":"8.77","upperLimit":"10.87","value":"9.7"}]}],"title":"Prostate specific concern"}],"denoms":[{"counts":[{"groupId":"OG000","value":"557"},{"groupId":"OG001","value":"543"}],"units":"Participants"}],"description":"The time to definitive deterioration (10% decrease in score from baseline) was assessed for the individual sub-scales (Physical Well-Being; Social/Family Well-Being; Emotional Well-Being; Functional Well-Being; Prostate-Specific Concerns). Analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG001","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on FACT-P population.","reportingStatus":"POSTED","timeFrame":"From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)","title":"Time to Definitive Deterioration of Score by 10% From Baseline on FACT-P Sub-Scales","type":"SECONDARY","unitOfMeasure":"months"}